Back HIV/AIDS

HIV / AIDS

AIDS 2014: Criminalization of Sex Work Increases Vulnerability to HIV

Sex workers from more than 30 countries came together this week at the Sex Worker Pre-Conference preceding the 20th International AIDS Conference in Melbourne to consider proposed changes to policy and funding approaches aimed at positioning human rights as critical to the response to HIV/AIDS.

alt

AIDS 2014: iPrEx OLE Shows PrEP Works, but Many Don't Take It [VIDEO]

The open-label extension of the iPrEx study found that Truvada pre-exposure prophylaxis (PrEP) was highly The open-label extension of the iPrEx study found that Truvada pre-exposure prophylaxis (PrEP) was highly effective among gay men who took it regularly to prevent HIV, but many did not do so, researchers reported this week at the 20th International AIDS Conference in Melbourne.

alt

AIDS 2014: Anal Lesions Often Resolve Without Treatment In HIV Positive Gay Men

High-grade anal dysplasia is common among gay men living with HIV, but it often resolves spontaneously and routine treatment may not be beneficial, according to results from the Australian SPANC study presented this week at the 20th International AIDS Conference in Melbourne.

alt

AIDS 2014: Romidepsin Activates Latent HIV, But Does Not Decrease Viral Reservoir

The HDAC inhibitor romidepsin was able to awaken latent HIV in resting T-cells, causing it to start producing new virus, but this was not associated with a decrease in the size of the viral reservoir in T-cells, researchers reported at the 20th International AIDS Conference this week in Melbourne. This finding suggests that kicking HIV out of hiding will not be adequate for a functional cure without strengthening immune response against the virus.

alt

AIDS 2014: iPrEx OLE Shows PrEP Effectiveness Is 100% for Those Taking 4 or More Doses per Week

iPrEx OLE, the open-label extension of the iPrEx study of pre-exposure prophylaxis (PrEP), reported its main findings this week at the 20th International AIDS Conference in Melbourne, Australia, published simultaneously in The Lancet Infectious Diseases. Overall PrEP effectiveness was 50% overall, but 100% in those taking 4 or more doses per week. There was a substantial early drop-out rate, especially among young people.

alt

AIDS 2014: Maraviroc Fails To Match Truvada for First-Line HIV Treatment

A NRTI-sparing dual antiretroviral regimen containing maraviroc (Selzentry) plus ritonavir-boosted darunavir (Prezista) was found to be less effective than a standard combination with tenofovir/emtricitabine (the drugs in Truvada), according to findings from the MODERN study presented this week at the 20th International AIDS Conference in Melbourne.

alt

AIDS 2014: Harm Reduction Funding Is Meeting Only 7% of Global Need

International donors are investing only 7% of what is needed to provide adequate harm reduction coverage for people who inject drugs, according to findings from a report presented this week at the 20th International AIDS Conference in Melbourne. A global commitment to re-balance spending on drug control and harm reduction is essential in order to achieve control of HIV and viral hepatitis among drug injectors, several speakers told the conference.

alt